Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies.
Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients.
The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018.
Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 10, 24 | -0.90 Decreased by -63.64% | -0.95 Increased by +5.26% |
| Feb 29, 24 | -0.99 Decreased by -102.04% | -0.86 Decreased by -15.12% |
| Nov 13, 23 | -0.71 Increased by +22.83% | -0.68 Decreased by -4.41% |
| Aug 11, 23 | -0.60 Increased by +22.08% | -0.63 Increased by +4.76% |
| May 15, 23 | -0.55 Increased by +25.68% | -0.67 Increased by +17.91% |
| Mar 17, 23 | -0.49 Increased by +47.31% | -0.80 Increased by +38.75% |
| Nov 4, 22 | -0.92 Decreased by -31.43% | -0.74 Decreased by -24.32% |
| Aug 4, 22 | -0.77 Increased by +7.23% | -0.86 Increased by +10.47% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -39.66 M Decreased by -13.33% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -31.08 M Decreased by -14.23% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -23.37 M Increased by +10.15% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -20.48 M Increased by +36.82% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -34.99 M Decreased by -43.83% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -27.21 M Increased by +5.95% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -26.01 M Decreased by -72.35% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -32.42 M Decreased by -9.13% | Decreased by N/A% Decreased by N/A% |